BioCentury
ARTICLE | Clinical News

Cidara reports Phase II data for IV antifungal rezafungin

April 20, 2018 7:49 PM UTC

Cidara Therapeutics Inc. (NASDAQ:CDTX) reported top-line data from 92 patients with candidemia and/or invasive candidiasis in the modified intent-to-treat (ITT) population of the Phase II STRIVE trial showing that once-weekly 400 mg IV rezafungin (formerly CD101 IV) led to an overall success rate, defined as achieving clinical and mycological cure, at day 14 of 72.7% compared with 71.4% for once-daily IV caspofungin. A 400 mg dose of rezafungin for one week followed by once-weekly 200 mg rezafungin led to an overall success rate at day 14 of 74.2%. Cidara said the double-blind, international trial was not powered for superiority or non-inferiority.

In mid-2018, Cidara plans to start the Phase III ReSTORE and ReSPECT trials of rezafungin. Top-line data from ReSTORE to treat invasive fungal infections are expected in 2020, while an interim futility analysis of ReSPECT to prevent invasive fungal infections in patients undergoing an allogeneic bone marrow transplant is expected in 2019...

BCIQ Company Profiles

Cidara Therapeutics Inc.